Llagas, Rizelda .
HRN: 21-89-81 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/21/2022
CEFUROXIME 500MG (TAB)
09/21/2022
09/27/2022
PO
500MG
BID
S/P LTCS
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft TissueIntra-abdominal Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes